Yttrium (90Y) tacatuzumab tetraxetan
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | α-fetoprotein |
| Clinical data | |
| Identifiers | |
476413-07-7  | |
| None | |
| Chemical data | |
| Formula | C6470H9971N1712O2007S4290Y |
| 145 kDa | |
| (what is this?) (verify) | |
Yttrium (90Y) tacatuzumab tetraxetan (trade name AFP-Cide) is a humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.